NeuroMetrix, Inc. Announces Date for Third Quarter 2020 Financial Results Conference Call
NeuroMetrix, Inc. (Nasdaq:NURO) plans to report its Q3 2020 financial results on October 22, 2020, before market opening. A conference call will follow at 8:00 a.m. ET to discuss the results and relevant business updates. Dial-in details include 844-787-0799 for the U.S. and 661-378-9630 internationally, with confirmation code 9786945. The earnings release and financial statements will be available on the company's website. NeuroMetrix specializes in neurostimulation-based medical devices and has three FDA-cleared products.
- Company plans to release Q3 2020 financial results, indicating transparency and shareholder engagement.
- NeuroMetrix has three FDA-cleared commercial products, showcasing strong compliance with regulatory standards.
- None.
WOBURN, Mass., Oct. 15, 2020 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (Nasdaq:NURO) announced today that it plans to issue its 2020 third quarter financial results before the opening of the market on October 22, 2020. The Company will host a conference call at 8:00 a.m., Eastern Time on October 22, 2020 to discuss its financial results as well as business developments affecting the Company.
The conference call may be accessed in the United States by dialing 844-787-0799 and using the confirmation code 9786945. Internationally, the conference call may be accessed by dialing 661-378-9630 and using the same confirmation code. The earnings press release and accompanying condensed financial statements will be accessible from the Company's website at www.NeuroMetrix.com under the "Investor Relations" tab.
A replay of the conference call will be available starting two hours after the call by dialing 855-859-2056, domestically and 404-537-3406, internationally. The confirmation code to access the replay is 9786945. The replay will be available for one week after the conference call.
About NeuroMetrix
NeuroMetrix is a leading developer and manufacturer of diagnostic and therapeutic neurostimulation-based medical devices that are used throughout the world. The Company has three FDA cleared commercial products. DPNCheck® is a point-of-care test that is used to evaluate peripheral neuropathies. ADVANCE™ is a point-of-care device that provides nerve conduction studies as an aid in diagnosing and evaluating patients suspected of having focal or systemic neuropathies. Quell® is a wearable, mobile app enabled, neurostimulation device indicated for symptomatic relief and management of chronic pain and is available over-the-counter. The Company maintains an active, industry-leading R&D program. For more information, visit NeuroMetrix.com.
NeuroMetrix, Inc.
Thomas T. Higgins, 781-314-2761
SVP and Chief Financial Officer
neurometrix.ir@neurometrix.com
Source: NeuroMetrix, Inc.
FAQ
When will NeuroMetrix release its Q3 2020 financial results?
What time is the NeuroMetrix conference call for Q3 2020 results?
How can I access NeuroMetrix's Q3 2020 earnings press release?
What are some products offered by NeuroMetrix?
